Cliff Lane, National Institutes of Health, discusses the most recent studies in the use of Interleukin-2 in boosting CD-4+ cells and the clinical outcomes for people with HIV.
He also explains the differences between the innate an adaptive immune systems.
Interviewed at the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009.
i still see studies that have come out after that show increased response to IL2 in certain cancers (this focuses on HIV)....but still an overall low response rate less than or around 20%
ghettogeekmike 1 year ago
good video....first comment*****
cray32 1 year ago